Ocular Therapeutix, Inc. Earnings Recaps
Q3 2025
Nov 5, 2025
Ocular Therapeutix reported strong progress in its third quarter of 2025 with key milestones reached in its clinical trials for AXPAXLI, positioning the company for a potential market shift in retinal therapies.
Key takeaways
- Successfully reached target randomization of 555 subjects in the SOL-R trial for wet AMD, indicating strong investigator engagement and execution.
- Launched the HELIOS program aimed at gaining a superiority label for AXPAXLI in both diabetic retinopathy and non-proliferative diabetic retinopathy (NPDR), aiming to capture a broader patient population.
- Phase III trial SOL-1 anticipates releasing top-line data in Q1 2026, which could position AXPAXLI as a distinct first-line treatment in a commoditized market currently dominated by anti-VEGF therapies.